Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors

Newton, MA [February 4, 2026] — Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies. Dr. Blanchard most recently served as President, CEO, and Director of Anika Therapeutics (NASDAQ: ANIK), where she led the successful implementation of a high-growth commercial strategy. During her tenure, Anika divested non-core assets, commercialized innovative regenerative orthopedic and osteoarthritis pain products, delivered double-digit commercial channel growth, and advanced multiple programs through U.S. clinical and regulatory pathways. Dr. Blanchard will remain on the Anika Board as Executive Chair. Her prior leadership roles include serving as CEO of Microchips Biotech and as Senior Vice President & Chief Scientific Officer of Zimmer. “Cheryl brings a rare combination of scientific depth, operational rigor, commercial leadership, and board experience—paired with a proven track record of transforming organizations and launching category-defining products,” said Andrey J. Zarur, Ph.D., Co-Founder & Chairman of the Board of Directors of Lumicell. “Her strategic acumen and her commitment to patient-focused innovation will be tremendously valuable as Lumicell continues our mission to bring LumiSystem™ to more surgeons and patients.” Dr. Blanchard is a seasoned board director with service across public, private, and private-equity-backed companies, including Vigil Neuroscience, Daré Bioscience, SeaSpine Holdings, Neuronetics, CeramTec, ISTO Technologies, and the Massachusetts Biotechnology Council. She is widely recognized as an industry leader and is a member of the National Academy of Engineering, and a Fellow of the American Institute for Medical and Biological Engineering. “Lumicell’s technology has the potential to meaningfully elevate standards of care in cancer surgery,” said Dr. Blanchard. “I’m honored to join the Board at this pivotal time and look forward to working with the team to support the company’s next phase of growth and scale impact.” About Lumicell Lumicell is a privately held life sciences company revolutionizing the intraoperative detection of cancer with its real-time fluorescence imaging technology. Lumicell’s proprietary technology is FDA-approved for use in the treatment of breast cancer and is also being explored for further development across a wide variety of solid tumor indications. For more information, please visit www.Lumicell.com and www.Lumisystem.com. Follow the company on Facebook, X, and LinkedIn. This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this press release reflect Lumicell’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions, and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the regulatory process to approve pharmaceutical drugs or medical devices. Media Contact: [email protected] Manage Cookie Consent To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent

The release as fetched from its publisher. lumicell.com ↗